收藏切换
Efficacy and safety analysis of icotinib hydrochloride combined with intensity modulated radiation therapy in the treatment of brain metastases from epidermal growth factor receptor mutation-positive lung adenocarcinoma
收藏切换
Xudong GUO1, Zhiwei WANG2, Xin HOU2
World Clinical Drug | 2022, 43(9) : 1118 - 1123
Less
收藏切换
World Clinical Drug | 2022, 43(9): 1118-1123
• Article •
Efficacy and safety analysis of icotinib hydrochloride combined with intensity modulated radiation therapy in the treatment of brain metastases from epidermal growth factor receptor mutation-positive lung adenocarcinoma
Full
Xudong GUO1, Zhiwei WANG2, Xin HOU2
Affiliations
  • 1.Department of General Medicine, the First Affiliated Hospital of Henan University, Kaifeng 450051, Henan Province, China
  • 2.Department of Oncology Ward 1, the First Affiliated Hospital of Henan University, Kaifeng 450051, Henan Province, China
Published: 2022-09-10 doi: 10.13683/j.wph.2022.09.007
Outline
收藏切换
Objective

To analyze the efficacy and safety of icotinib hydrochloride combined with intensity-modulated radiation therapy (IMRT) in the treatment of brain metastases from epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma.

Methods

One-hundred cases of brain metastases patients from EGFR mutation-positive lung adenocarcinoma admitted to the first affiliated hospital of Henan university from April 2017 to April 2019 were retrospectively analyzed, and they were divided into the targeted therapy group (n=50) and the combined therapy group (n=50) according to the treatment method. The targeted therapy group were treated with icotinib hydrochloride, and the combined therapy group received IMRT treatment on the basis of the targeted therapy group. After four months of targeted therapy, the short-term curative effects of the two groups were evaluated, the occurrence of adverse reactions in the two groups were counted, the levels of serum tumor markers (carcinoembryonic antigen, carbohydrate antigen 19-9, and cytokeratin 19 fragment antigen 21-1) were detected at the time of enrollment and four months after targeted therapy, and the two-year survival rate was followed up.

Results

The objective remission rate in the combined therapy group was 82.00%, which was significantly higher than 58.00% in the targeted therapy group (P<0.05). The adverse reactions such as rash, nausea and vomiting, fatigue, bone marrow suppression, diarrhea, liver and kidney injury in the two groups were all in the grade Ⅰ to Ⅲ, which were tolerated by the patients. There was no significant difference in the grade of adverse reactions between the two groups (P>0.05). After four months of targeted therapy, the levels of serum tumor markers in the two groups were significantly lower than those in the same group when joining the group (P<0.05), and the combined therapy group were significantly lower than those in the targeted therapy group in the same period (P<0.05). The two-year survival rate of the combined therapy group was 38.00%, which was significantly higher than that in the targeted therapy group (20.00%)(P<0.05).

Conclusion

Icotinib hydrochloride combined with IMRT in the treatment of brain metastasis from EGFR mutation-positive lung adenocarcinoma can achieve better short-term and long-term effects, and the adverse reactions are mild and can tolerated by the patients.

icotinib hydrochloride  /  intensity modulated radiation therapy  /  epidermal growth factor receptor  /  brain metastases from lung adenocarcinoma
郭旭东, 王志伟, 侯欣. 盐酸埃克替尼联合调强放疗对表皮生长因子受体突变阳性肺腺癌脑转移的有效性及安全性分析. 世界临床药物, 2022 , 43 (9) : 1118 -1123 . DOI: 10.13683/j.wph.2022.09.007
Xudong GUO, Zhiwei WANG, Xin HOU. Efficacy and safety analysis of icotinib hydrochloride combined with intensity modulated radiation therapy in the treatment of brain metastases from epidermal growth factor receptor mutation-positive lung adenocarcinoma[J]. World Clinical Drug, 2022 , 43 (9) : 1118 -1123 . DOI: 10.13683/j.wph.2022.09.007
Year 2022 volume 43 Issue 9
5
0
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.09.007
  • Receive Date:2021-10-28
  • Online Date:2026-11-19
  • Published:2022-09-10
Article Data
Affiliations
History
  • Received:2021-10-28
Funding
Affiliations
    1.Department of General Medicine, the First Affiliated Hospital of Henan University, Kaifeng 450051, Henan Province, China
    2.Department of Oncology Ward 1, the First Affiliated Hospital of Henan University, Kaifeng 450051, Henan Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.09.007
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT